SCHEMBL6340701

SCHEMBL6340701

COc1cc(NS(=O)(=O)c2cn(C)c3ccc(N)cc23)cc(OC)c1OC

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.49
HTT P42858 2/20 0.49
PKM P14618 2/20 0.49
LMNA P02545 1/20 0.49
MAPK1 P28482 1/20 0.49
RXFP1 Q9HBX9 1/20 0.44
GAA P10253 3/20 0.43
L3MBTL1 Q9Y468 1/20 0.41
TP53 P04637 4/20 0.39
MAPT P10636 2/20 0.39
THRB P10828 1/20 0.38
BRD4 O60885 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
HTR6 P50406 1/20 0.38
CPT2 P23786 1/20 0.38
CPT1A P50416 1/20 0.38
CPT1B Q92523 1/20 0.38
SHMT2 P34897 1/20 0.37
HSD17B10 Q99714 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6342356 0.83 HTT (0.46) SMN1; SMN2HTTPKMLMNAMAPK1
SCHEMBL6351407 0.76 TUBB4A (0.53) SMN1; SMN2HTTPKMLMNAMAPK1
SCHEMBL28051135 0.75 HTT (0.52) SMN1; SMN2HTTPKMLMNAMAPK1
SCHEMBL28298620 0.75 HTT (0.57) SMN1; SMN2HTTPKMLMNAMAPK1
SCHEMBL6350411 0.73 HTR6 (0.65) SMN1; SMN2HTTPKMLMNAMAPK1
SCHEMBL31687144 0.73 HTT (0.55) SMN1; SMN2HTTPKMLMNAMAPK1
SCHEMBL31687177 0.73 IMPDH2 (0.54) SMN1; SMN2HTTPKMLMNAMAPK1
SCHEMBL6588640 0.71 CA12 (0.46) PKMHSP90AB1
SCHEMBL5189520 0.71 SMN1; SMN2 (0.59) SMN1; SMN2HTTPKMLMNAMAPK1
SCHEMBL6588546 0.70 HTT (0.49) SMN1; SMN2HTTPKMLMNAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050187246-A1 Cell proliferation inhibitors LI QUN (US) 2005-08-25 US claimed
EP-1181269-B1 CELL PROLIFERATION INHIBITORS ABBOTT LAB (US) 2004-02-25 EP claimed
US-20030096856-A1 Cell proliferation inhibitors ABBVIE INC. 2003-05-22 US claimed
US-6521658-B1 Cell proliferation inhibitors ABBOTT LABORATORIES 2003-02-18 US claimed
EP-1181269-A1 CELL PROLIFERATION INHIBITORS ABBOTT LABORATORIES (US) 2002-02-27 EP claimed
WO-2000073264-A1 CELL PROLIFERATION INHIBITORS ABBOTT LABORATORIES (US) 2000-12-07 WO claimed
US-20050187246-A1 Cell proliferation inhibitors LI QUN (US) 2005-08-25 US disclosed
US-6924304-B2 Cell proliferation inhibitors ABBOTT LABORATORIES (US) 2005-08-02 US disclosed
EP-1181269-B1 CELL PROLIFERATION INHIBITORS ABBOTT LAB (US) 2004-02-25 EP disclosed
US-20030096856-A1 Cell proliferation inhibitors ABBVIE INC. 2003-05-22 US disclosed
US-6521658-B1 Cell proliferation inhibitors ABBOTT LABORATORIES 2003-02-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030096856-A1 Cell proliferation inhibitors MKI67, CCNI, CCNA1 SMN1; SMN2 1869/4885HTT 4313/4885PKM 1894/4885
US-20050187246-A1 Cell proliferation inhibitors MKI67, CCNI, CCNC SMN1; SMN2 2093/4885HTT 4031/4885PKM 1733/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.